For example, the intravenous infusion of an adeno-associated viral (AAV) vector containing full-length copies of survival motor neuron 1 (SMN1) has shown success in treating spinal muscular atrophy type 1 (SMA1), a disease characterized by motor neuron degeneration [171]. This evidence concerns the gene SMN1 and spinal muscular atrophy, type 1.